Literature DB >> 27913494

Introduction to cancer genetic susceptibility syndromes.

Rose B McGee1, Kim E Nichols1.   

Abstract

The last 30 years have witnessed tremendous advances in our understanding of the cancer genetic susceptibility syndromes, including those that predispose to hematopoietic malignancies. The identification and characterization of families affected by these syndromes is enhancing our knowledge of the oncologic and nononcologic manifestations associated with predisposing germ line mutations and providing insights into the underlying disease mechanisms. Here, we provide an overview of the cancer genetic susceptibility syndromes, focusing on aspects relevant to the evaluation of patients with leukemia and lymphoma. Guidance is provided to facilitate recognition of these syndromes by hematologists/oncologists, including descriptions of the family history features, tumor genotype, and physical or developmental findings that should raise concern for an underlying cancer genetic syndrome. The clinical implications and management challenges associated with cancer susceptibility syndromes are also discussed.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27913494      PMCID: PMC6142512          DOI: 10.1182/asheducation-2016.1.293

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  40 in total

Review 1.  Predisposition to pediatric and hematologic cancers: a moving target.

Authors:  David Malkin; Kim E Nichols; Kristin Zelley; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

2.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

Review 3.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

4.  Unexpected findings in cancer predisposition genes detected by array comparative genomic hybridisation: what are the issues?

Authors:  Gabriella Pichert; Shehla Nilofer Mohammed; Joo Wook Ahn; Caroline Mackie Ogilvie; Louise Izatt
Journal:  J Med Genet       Date:  2011-03-23       Impact factor: 6.318

5.  Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.

Authors:  Eduard Schulz; Angelika Valentin; Peter Ulz; Christine Beham-Schmid; Karin Lind; Verena Rupp; Herwig Lackner; Albert Wölfler; Armin Zebisch; Werner Olipitz; Jochen Geigl; Andrea Berghold; Michael R Speicher; Heinz Sill
Journal:  J Med Genet       Date:  2012-05-31       Impact factor: 6.318

6.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

8.  Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.

Authors:  Jane E Churpek; Rafael Marquez; Barbara Neistadt; Kimberly Claussen; Ming K Lee; Matthew M Churpek; Dezheng Huo; Howard Weiner; Mekhala Bannerjee; Lucy A Godley; Michelle M Le Beau; Colin C Pritchard; Tom Walsh; Mary-Claire King; Olufunmilayo I Olopade; Richard A Larson
Journal:  Cancer       Date:  2015-12-07       Impact factor: 6.860

9.  Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.

Authors:  Kasmintan A Schrader; Donavan T Cheng; Vijai Joseph; Meera Prasad; Michael Walsh; Ahmet Zehir; Ai Ni; Tinu Thomas; Ryma Benayed; Asad Ashraf; Annie Lincoln; Maria Arcila; Zsofia Stadler; David Solit; David M Hyman; David Hyman; Liying Zhang; David Klimstra; Marc Ladanyi; Kenneth Offit; Michael Berger; Mark Robson
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  7 in total

Review 1.  Tumour predisposition and cancer syndromes as models to study gene-environment interactions.

Authors:  Michele Carbone; Sarah T Arron; Bruce Beutler; Angela Bononi; Webster Cavenee; James E Cleaver; Carlo M Croce; Alan D'Andrea; William D Foulkes; Giovanni Gaudino; Joanna L Groden; Elizabeth P Henske; Ian D Hickson; Paul M Hwang; Richard D Kolodner; Tak W Mak; David Malkin; Raymond J Monnat; Flavia Novelli; Harvey I Pass; John H Petrini; Laura S Schmidt; Haining Yang
Journal:  Nat Rev Cancer       Date:  2020-05-29       Impact factor: 60.716

Review 2.  Imaging surveillance for children with predisposition to renal tumors.

Authors:  Abhay S Srinivasan; Sandra Saade-Lemus; Sabah E Servaes; Michael R Acord; Janet R Reid; Sudha A Anupindi; Lisa J States
Journal:  Pediatr Radiol       Date:  2019-10-16

Review 3.  Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.

Authors:  Margaret C S Boguszewski; Cesar L Boguszewski; Wassim Chemaitilly; Laurie E Cohen; Judith Gebauer; Claire Higham; Andrew R Hoffman; Michel Polak; Kevin C J Yuen; Nathalie Alos; Zoltan Antal; Martin Bidlingmaier; Beverley M K Biller; George Brabant; Catherine S Y Choong; Stefano Cianfarani; Peter E Clayton; Regis Coutant; Adriane A Cardoso-Demartini; Alberto Fernandez; Adda Grimberg; Kolbeinn Guðmundsson; Jaime Guevara-Aguirre; Ken K Y Ho; Reiko Horikawa; Andrea M Isidori; Jens Otto Lunde Jørgensen; Peter Kamenicky; Niki Karavitaki; John J Kopchick; Maya Lodish; Xiaoping Luo; Ann I McCormack; Lillian Meacham; Shlomo Melmed; Sogol Mostoufi Moab; Hermann L Müller; Sebastian J C M M Neggers; Manoel H Aguiar Oliveira; Keiichi Ozono; Patricia A Pennisi; Vera Popovic; Sally Radovick; Lars Savendahl; Philippe Touraine; Hanneke M van Santen; Gudmundur Johannsson
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

Review 4.  Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Authors:  Siegfried Janz; Fenghuang Zhan; Fumou Sun; Yan Cheng; Michael Pisano; Ye Yang; Hartmut Goldschmidt; Parameswaran Hari
Journal:  Front Genet       Date:  2019-05-08       Impact factor: 4.599

5.  CD20-negative primary middle ear diffuse large B-cell lymphoma coexpressing MYC and BCL-2 secondary to acute lymphoblastic leukemia: A case report.

Authors:  Chao Ding; Ying Huang; Mingxia Shi; Bo Nie; Yuntao Li; Kun Wu; Jinrong Yang; Yun Zeng
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

6.  Developmental disorders caused by haploinsufficiency of transcriptional regulators: a perspective based on cell fate determination.

Authors:  Roman Zug
Journal:  Biol Open       Date:  2022-01-28       Impact factor: 2.422

Review 7.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.